A Lifelong Commitment to Rural Cancer Care | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
A Lifelong Commitment to Rural Cancer Care | Targeted Oncology …
2 months ago
targetedonc.com
Sequencing in the cGVHD Treatment Paradigm | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Sequencing in the cGVHD Treatment Paradigm | Targeted Oncology - I…
1 month ago
targetedonc.com
Lurbinectedin and Tarlatamab in ES-SCLC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Lurbinectedin and Tarlatamab in ES-SCLC | Targeted Oncology - Immu…
4 months ago
targetedonc.com
Mechanism of Action & Potential Impact of Tislelizumab | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mechanism of Action & Potential Impact of Tislelizumab | Targeted …
3 months ago
targetedonc.com
Giredestrant Yields Lower Treatment Discontinuation vs SOC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Giredestrant Yields Lower Treatment Discontinuation vs SO…
2 months ago
targetedonc.com
Examining Biomarker Testing in Early-stage NSCLC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Examining Biomarker Testing in Early-stage NSCLC | Targeted Onc…
2 months ago
targetedonc.com
Sequencing Strategies and Integration of Emerging Therapies | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Sequencing Strategies and Integration of Emerging Therapie…
5 months ago
targetedonc.com
Efficacy of TCE-Pomalidomide Salvage Therapy in RRMM | Target…
2 months ago
targetedonc.com
ASCENT-03 Results: Sacituzumab Govitecan in First-Line TNBC | Tar…
2 months ago
targetedonc.com
Modern Relapsed Myeloma Population Is Addressed in Majes…
1 month ago
targetedonc.com
Beyond SC Daratumumab: Emerging Therapeutic Approache…
3 months ago
targetedonc.com
Breakthroughs in Oncology: Validating Real Gains in Cancer S…
1 month ago
targetedonc.com
Leveraging ctDNA Status to Guide Treatment Strategies in Breast Ca…
3 months ago
targetedonc.com
Dr Mayer on Giredestrant's Success in Early Breast Cancer | Targeted …
2 months ago
targetedonc.com
RB-1355 and the Evolution of Antitumoral Macrophage Therapy …
2 weeks ago
targetedonc.com
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadju…
2 months ago
targetedonc.com
Latest Advances in Lymphoma and CLL Treatment: Insights From Dr …
2 months ago
targetedonc.com
The Evolving Role of HPV Stratification and Therapeutic De-…
2 months ago
targetedonc.com
The Mechanism of Action of Olaparib | Targeted Oncology - Im…
Jul 30, 2013
targetedonc.com
Drawing Comparisons for Relevant Therapies in Patients With DLBCL …
Dec 9, 2024
targetedonc.com
First-Line Cytoreductive Selection: Hydroxyurea Vs Interferon Consid…
10 months ago
targetedonc.com
Dr Necchi on TAR-200 & Cetrelimab in Bladder Cancer | Targeted Onco…
4 months ago
targetedonc.com
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial …
2 months ago
targetedonc.com
KEYNOTE-811: Clinical Outcomes and Safety of Pembrolizumab Tras…
3 months ago
targetedonc.com
Optimizing Treatment: Adjusting Somatostatin Analog Dosing for N…
4 months ago
targetedonc.com
Using Guidelines and CABINET Data to Inform Treatment Sequencing i…
4 weeks ago
targetedonc.com
Targeting the CDK 4/6 Pathway: Clinical Insights from the Phase 2 …
1 month ago
targetedonc.com
The Targeted Pulse: CAR T Label Updates, FDA Approvals, and Mor…
8 months ago
targetedonc.com
1:45
Unmet Needs and Therapy Modifications Relevant in the CR…
9 months ago
targetedonc.com
1:41
Dose Escalation of Luspatercept Is Underutilized in MDS | Targeted O…
Jan 6, 2025
targetedonc.com
See more videos
Static thumbnail place holder